This study investigated the use of late dose intensification therapy (LDIT) with
cyclophosphamide (180 mg/kg) and VP 16 (1 g/m 2) plus autologous bone marrow rescue in …

In nine patients with recurrent or refractory small cell lung cancer a phase II study with high-
dose cyclophosphamide and high-dose VP 16-213 with autologous bone marrow …

Whithin an original consecutive series of 94 patients, 36 eligible patients with small cell lung
carcinoma were treated with high-dose cyclophosphamide 7 g/m 2 after conventional …

A multicentric randomized prospective trial was conducted to test whether late intensification
chemotherapy would increase the remission rate, the relapse-free survival, and the survival …

Forty-four patients with small cell lung cancer were treated with an intensive chemotherapy
induction program consisting of combination cyclophosphamide, Adriamycin, and vincristine …

One hundred eleven patients with inoperable but limited‐stage small cell lung cancer were
treated with three courses of cyclophosphamide (1.5, 2.5, and 3.5 g/m2, respectively) and …

Fifty-seven patients with small cell lung cancer (SCLC)(limited disease= LD in 23, extensive
disease= ED in 34) received the combination of CCNU, cyclophosphamide, vincristine and …

In a pilot study, 21 consecutive eligible patients with extensive-stage small cell carcinoma of
the lung were scheduled for treatment with combination chemotherapy followed by total …

PURPOSE The primary objective of this randomized prospective study was to compare the
survival of limited-stage small-cell lung cancer (SCLC) patients treated with chemotherapy …

Small cell lung cancer (SCLC) constitutes 20-25% of all primary carcinomas of the lung.
Over the past 15 years it has become clear that in terms ofbiologic behaviour and response …